HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
BIOBOARD - UNITED KINGDOM
Pioneering drug discovery gets major funding to move to next stage
A pioneering drug development team at the University of Aberdeen has received a £1.5M funding boost to accelerate the progress of multiple novel drug leads to tackle cancer and diseases such as debilitating inflammatory conditions

Scottish Enterprise and Biotechnology and Biological Sciences Research Council have provided financial support for the innovative work which takes to the next level research first developed at the University a decade ago, that created novel therapies based on the immune system of one of the most ancient species on the planet - sharks.

The next-generation technologies now being developed - which will be spun out out of the University into a company later this year - uses small man-made proteins closely related to structures called Variable Novel Antigen Receptors (VNARS), found in the shark immune system. VNARs are the smallest molecule of this type identified so far in the animal kingdom.

The VNARs engineered by the team in the lab are the same size, and are being used to develop new drugs as well as to deliver - in a more tailored way - drugs into the body. Their small size will provide better penetration of solid cancer tumors and also make them capable of crossing into the brain. Their size, and less complicated structure, also potentially makes them much cheaper medicines than other related therapies. 

The team, comprising ex-industry professionals and leading academics, have successfully produced over 10 billion of these drug-like molecules. They say their VNAR drug library is the “equivalent to having access to 10,000 sharks without needing to keep a single animal in an aquarium”.  From this drug library they have already successfully gone “fishing” for new therapies to conditions such as cancer or inflammation. 

One of the team's VNARs can significantly extend the effective life of existing and new drugs in the body.  Typically drugs have to be taken every few hours. However, if joined to the new VNAR, their useful potency can be increased from hours to weeks. Other VNARs can specifically recognize, target and then destroy cancer cells.   By the end of this funding period the Aberdeen team aim to have produced drug candidates that not only have a long half-life but can also seek out and deliver deep into tumors powerful toxins that are tailor-made to kill cancer cells.  

The University's Professor Andy Porter and Dr. Caroline Barelle are heading up the research. They have already had success with the drug discovery company Haptogen Ltd - a University of Aberdeen spin-out that was bought by the US pharmaceutical company Wyeth Inc in 2007.

Professor Porter, Professor of Biotechnology and Director of the Scottish Biologics Facility, said: “We are excited and delighted with the support we have received from Scottish Enterprise and BBSRC for our research. These next-generation, targeted therapies show the potential to be more effective than current approaches, with less side-effects for patients and reduced costs of drug manufacture.” 

Dr. Barelle, Senior Research Fellow, added:  We have already received commercial interest in our progress to date and I hope to use my industry background to help turn our exciting drug leads into a new successful biotechnology company which we will spin-out from the University of Aberdeen.”

Professor Stephen Logan, Senior Vice-Principal for the University of Aberdeen, said: “This is ambitious and exciting research which will help build on Aberdeen's reputation as Scotland's commercial capital for drug discovery.”

Julia Brown, Director of Foresighting, Scottish Enterprise added: “Scottish Enterprise recognizes the international strength of the biologics research and commercialization capabilities of the University of Aberdeen and is pleased to be able to support this innovative project.  The technology involved has huge potential and the challenge now is to help translate this into a successful company, located in Scotland.”

Click here for the complete issue.

NEWS CRUNCH  
news Vitafoods Asia 2017 heralds a new future of innovation
news Sanner receives Zero Defect Award
news AdAlta pioneers novel drug for rare lung disease
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy